The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: A population-based cohort study

BJU International

Volumn 98, Issue 5, 2006, Pages 973-978

  Barry, Michael J ^a   Delorenzo, Michael A ^b   Walker Corkery, Elizabeth S ^a   Lucas, F Lee ^b   Wennberg, David C ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Maine Medical Center   (United States)

Author keywords

Androgen deprivation; Epidemiology; Prostate cancer; Prostate specific antigen

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER DIAGNOSIS; COHORT ANALYSIS; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; ORCHIECTOMY; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; UNITED STATES;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; COHORT STUDIES; CROSS-SECTIONAL STUDIES; HUMANS; MALE; ORCHIECTOMY; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 33749539357     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06416.x     Document Type: Article

References (34)

1. Brawley O. Prostate carcinoma incidence and patient mortality: the effects of screening and early detection. Cancer 1997; 80: 1857-63
2. Farkas A, Schneider D, Perrotti M, Cummings KB, Ward WS. National trends in the epidemiology of prostate cancer, 1973-94: evidence for the effectiveness of prostate-specific antigen screening. Urology 1998; 52: 444-9
3. Garnick MB. Hormonal therapy in the management of prostate cancer: from Huggins to the present. Urology 1997; 49 (Suppl. 3A): 5-15
4. Chodak G, Keane T, Klotz L; The Hormone Therapy Study Group. Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology 2002; 60: 201-8
5. Herr HW, O'Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 2000; 163: 1743-6
6. Lubeck DP, Grossfeld GD, Carroll PR. The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer. Urology 2001; 58 (Suppl. 2): 94-100
7. Fowler FJ Jr, McNaughton Collins M, Walker Corkery E, Elliott DB, Barry MJ. The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma. Cancer 2002; 95: 287-95
8. Mariani AJ, Glover M, Arita S. Medical versus surgical androgen suppression therapy for prostate cancer: a 10-year longitudinal cost study. J Urol 2001; 165: 104-7
9. Catalona WJ. Screening for prostate cancer: enthusiasm. Urology 1993; 42: 113-5
10. Andriole GL. The case for prostate cancer screening. Semin Urol 1993; 11: 50-3
11. Coley CM, Barry MJ, Fleming C, Fahs MC, Mulley AG. Early detection of prostate cancer. Part II: Estimating the risks, benefits and costs. American College of Physicians. Ann Intern Med 1997; 126: 468-79
12. Tombal B, De Visccher L, Cosyns J et al. Assessing the risk of unsuspected prostate cancer in patients with benign prostatic hypertrophy: a 13-year retrospective study of the incidence and natural history of T1a-T1b prostate cancers. BJU Int 1999; 84: 1015-20
13. Zigeuner RE, Lipsky K, Riedler I et al. Did the rate of incidental prostate cancer change in the era of PSA testing? A retrospective study of 1127 patients. Urology 2003; 62: 451-5
14. Schroder FH, van der Maas P, Beemsterboer P et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 1998; 90: 1817-23
15. Wennberg J, Cooper M. The Dartmouth Atlas of Health Care in the United States. Chicago, IL: American Hospital Publishing, Inc., 1998
16. Ries L, Eisner M, Kosary C et al. SEER Cancer Statistics Review 1975-2001. Bethesda, MD: National Cancer Institute, 2004
17. Meng MV, Grossfeld GD, Sadetsky N, Mehta SS, Lubeck DP, Carroll PR. Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology 2002; 60 (Suppl. 3A): 7-12
18. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for prostate cancer. J Natl Cancer Inst 2003; 95: 981-9
19. Zietman A, Thakral H, Skowronski U, Shipley W. Freedom from castration: an alternative end point for men with localized prostate cancer treated by external beam radiation therapy. Int J Radiat Oncol Biol Phys 2002; 53: 1152-9
20. Mehta SS, Lubeck DP, Sadetsky N, Pasta DJ, Carroll PR. Patterns of secondary cancer treatment for biochemical failure following radical prostatectomy: data from CaPSURE. J Urol 2004; 171: 215-9
21. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-7
22. Potosky AL, Knopf K, Clegg LX et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001; 19: 3750-7
23. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 1997; 79: 235-46
24. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with nodepositive prostate cancer. N Engl J Med 1999; 341: 1781-8
25. Bolla M, Collette L, Blank L et al. Longterm results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-6
26. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292: 821-7
27. Aronson A, Seidenfeld J, Samson D et al. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Rockville, MD: Agency for Health Care Policy and Research, 1999
28. Oottamasathien S, Crawford ED. Should routine screening for prostate-specific antigen be recommended? Arch Intern Med 2003; 163: 661-2
29. Oliver SS, Gunnell D, Donovan JL. Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet 2000; 355: 1788-9
30. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 2002; 325: 740-5
31. Albertsen PC. The prostate cancer conundrum. J Natl Cancer Inst 2003; 95: 930-1
32. Merrill RM, Weed DL, Feuer EJ. The lifetime risk of developing prostate cancer in white and black men. Cancer Epidemiol Biomarkers Prev 1997; 6: 763-8
33. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA 2003; 289: 1414-20
34. Ross LE, Coates RJ, Breen N, Uhler RJ, Potosky AL, Blackman D. Prostatespecific antigen test use reported in the 2000 National Health Interview Survey. Prev Med 2004; 38: 732-44